MiR-143 Targets IGF-1R to Suppress Autoimmunity in Thyroid-Associated Ophthalmopathy

References

• Huang Y, Fang S, Zhang S, Zhou H. Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development. Taiwan J Ophthalmol. 2020;10:174–180. doi:10.4103/tjo.tjo_18_20
   PubMedGoogle Scholar
• Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5:134–142. doi:10.1016/S2213-8587(16)30046-8
   PubMed Web of Science ®Google Scholar
• Şahlı E, Gündüz K. Thyroid-associated ophthalmopathy. Turk J Ophthalmol. 2017;47:94–105. doi:10.4274/tjo.80688
   PubMedGoogle Scholar
• Hodgson NM, Rajaii F. Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review. Ophthalmol Ther. 2020;9:21–33. doi:10.1007/s40123-019-00226-9
   PubMed Web of Science ®Google Scholar
• Krause G, Eckstein A, Schülein R. Modulating TSH receptor signaling for therapeutic benefit. Eur Thyroid J. 2020;9:66–77. doi:10.1159/000511871
   PubMed Web of Science ®Google Scholar
• Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological aspects of Graves’ ophthalmopathy. Biomed Res Int. 2019;2019:7453260. doi:10.1155/2019/7453260
   PubMed Web of Science ®Google Scholar
• Xia N, Ye X, Hu X, et al. Simultaneous induction of Graves’ hyperthyroidism and Graves’ ophthalmopathy by TSHR genetic immunization in BALB/c mice. PLoS One. 2017;12:e0174260. doi:10.1371/journal.pone.0174260
   PubMed Web of Science ®Google Scholar
• Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–3470. doi:10.1210/jc.2005-2813
   PubMed Web of Science ®Google Scholar
• Krieger CC, Neumann S, Gershengorn MC. TSH/IGF1 receptor crosstalk: mechanism and clinical implications. Pharmacol Ther. 2020;209:107502. doi:10.1016/j.pharmthera.2020.107502
   PubMed Web of Science ®Google Scholar
• Krieger CC, Neumann S, Gershengorn MC. Is there evidence for igf1r-stimulating abs in Graves’ orbitopathy pathogenesis? Int J Mol Sci. 2020;21(18):21.
   Web of Science ®Google Scholar
• Smith TJ, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019;40:236–267. doi:10.1210/er.2018-00066
   PubMed Web of Science ®Google Scholar
• Smith TJ, Tsai CC, Shih MJ, et al. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18:983–988. doi:10.1089/thy.2007.0404
   PubMed Web of Science ®Google Scholar
• Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181:4397–4405. doi:10.4049/jimmunol.181.6.4397
   PubMed Web of Science ®Google Scholar
• Chen H, Mester T, Raychaudhuri N, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99:E1635–E1640. doi:10.1210/jc.2014-1580
   PubMed Web of Science ®Google Scholar
• Paik JS, Kim SE, Kim JH, Lee JY, Yang SW, Lee SB. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy. Immunobiology. 2020;225:151902. doi:10.1016/j.imbio.2019.151902
   PubMed Web of Science ®Google Scholar
• Jha S, Ting JP. Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases. J Immunol. 2009;183:7623–7629. doi:10.4049/jimmunol.0902425
   PubMed Web of Science ®Google Scholar
• Lu A, Wu H. Structural mechanisms of inflammasome assembly. FEBS J. 2015;282:435–444. doi:10.1111/febs.13133
   PubMed Web of Science ®Google Scholar
• Luo D, Liu F, Zhang J, et al. Functional crosstalk between long non-coding RNAs and the NLRP3 inflammasome in the regulation of diseases. Mol Immunol. 2021;131:191–200. doi:10.1016/j.molimm.2020.12.038
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.
   PubMed Web of Science ®Google Scholar
• Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol. 2005;175:1310–1319. doi:10.4049/jimmunol.175.2.1310
   PubMed Web of Science ®Google Scholar
• Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res. 2016;142:83–91. doi:10.1016/j.exer.2015.02.007
   PubMed Web of Science ®Google Scholar
• Pawlowski P, Poplawska I, Mysliwiec J, et al. Search of reference biomarkers reflecting orbital tissue remodeling in the course of Graves’ orbitopathy. Folia Histochemica Et Cytobiologica. 2020;58:37–45. doi:10.5603/FHC.a2020.0003
   PubMed Web of Science ®Google Scholar
• He Y, Franchi L, Núñez G. TLR agonists stimulate Nlrp3-dependent IL-1β production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol. 2013;190:334–339. doi:10.4049/jimmunol.1202737
   PubMed Web of Science ®Google Scholar
• Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1999;84:4079–4084. doi:10.1210/jcem.84.11.6111
   PubMed Web of Science ®Google Scholar
• Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100:142–150. doi:10.1136/bjophthalmol-2015-307399
   PubMed Web of Science ®Google Scholar
• Zhang L, Masetti G, Colucci G, et al. Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves’ disease and orbitopathy. Sci Rep. 2018;8:8386. doi:10.1038/s41598-018-26700-1
   PubMed Web of Science ®Google Scholar
• Hu ZJ, He JF, Li KJ, Chen J, Xie XR. Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB. Eur Rev Med Pharmacol Sci. 2017;21:1803–1809.
   PubMed Web of Science ®Google Scholar
• Thiel J, Alter C, Luppus S, et al. MicroRNA-183 and microRNA-96 are associated with autoimmune responses by regulating T cell activation. J Autoimmun. 2019;96:94–103. doi:10.1016/j.jaut.2018.08.010
   PubMed Web of Science ®Google Scholar
• Woeller CF, Roztocil E, Hammond C, Feldon SE. TSHR signaling stimulates proliferation through PI3K/Akt and induction of mir-146a and mir-155 in thyroid eye disease orbital fibroblasts. Invest Ophthalmol Vis Sci. 2019;60:4336–4345. doi:10.1167/iovs.19-27865
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang J, Pan Z, Zhang Y. miR-143-3p regulates cell proliferation and apoptosis by targeting IGF1R and IGFBP5 and regulating the Ras/p38 MAPK signaling pathway in rheumatoid arthritis. Exp Ther Med. 2018;15:3781–3790. doi:10.3892/etm.2018.5907
   PubMed Web of Science ®Google Scholar
• Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Euro J Endocrinol. 2021;185:G43–g67. doi:10.1530/EJE-21-0479
   PubMed Web of Science ®Google Scholar
• Wang J, Xiao Y, Zhang H. Role of miR-146a in the regulation of inflammation in an in vitro model of Graves’ orbitopathy. Invest Ophthalmol Vis Sci. 2016;57:6795. doi:10.1167/iovs.16-20559
   PubMed Web of Science ®Google Scholar
• Han SY, Choi SH, Shin JS, Lee EJ, Han SH, Yoon JS. High-mobility group box 1 is associated with the inflammatory pathogenesis of Graves’ orbitopathy. Thyroid. 2019;29:868–878. doi:10.1089/thy.2018.0285
   PubMed Web of Science ®Google Scholar
• Li H, Min J, Chen Y, Li H, Zhang Y. Polydatin attenuates orbital oxidative stress in Graves’ orbitopathy through the NRF2 pathway. Chem Biol Interact. 2020;315:108894. doi:10.1016/j.cbi.2019.108894
   PubMed Web of Science ®Google Scholar
• Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves’ disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011;210:369–377. doi:10.1530/JOE-11-0162
   PubMed Web of Science ®Google Scholar
• Coulter I, Frewin S, Krassas GE, Perros P. Psychological implications of Graves’ orbitopathy. Euro J Endocrinol. 2007;157:127–131. doi:10.1530/EJE-07-0205
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. Autoimmunity in Graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96:2386–2394. doi:10.1210/jc.2011-0307
   PubMed Web of Science ®Google Scholar
• Wei Y, Li N, Zhao L, et al. MicroRNAs and autoimmune-mediated eye diseases. Front Cell Dev Biol. 2020;8:818. doi:10.3389/fcell.2020.00818
   PubMed Web of Science ®Google Scholar
• Mohyi M, Smith TJ. IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol. 2018;61:T29–t43. doi:10.1530/JME-17-0276
   PubMed Web of Science ®Google Scholar
• Smith TJ. Teprotumumab as a novel therapy for thyroid-associated ophthalmopathy. Front Endocrinol. 2020;11:610337. doi:10.3389/fendo.2020.610337
   PubMed Web of Science ®Google Scholar
• Ali F, Chorsiya A, Anjum V, Ali A. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment. Int Ophthalmol. 2021;41:1549–1561. doi:10.1007/s10792-021-01706-3
   PubMed Web of Science ®Google Scholar